Frequency of Hepatocellular Carcinoma in Cirrhotic Patients after Chronic Hepatitis C Infection Treatment with Direct-Acting ‎Antivirals

Abstract

Backgroundand study aim: Hepatocellular carcinoma (HCC) is the 4 th most common cancer in Egypt and is the 2 nd leading cause of cancer-related death in both men and women. The aim of this study is to determine the frequency of HCC in cirrhotic patients admitted in Al-Ahrar Teaching hospital especially after hepatitis C virus (HCV) treatment with new direct-acting antivirals (DAAs). Patients and Methods:This study included 107 patients with liver cirrhosis admitted to Al-Ahrar Teaching hospital. All patients undergo complete blood count, liver functions, kidney functions, coagulation profiles, serology for viral hepatitis, serum alpha-fetoprotein, abdominal ultrasound, and tri-phasic computed tomography.Results: HCC was diagnosed in about 9 % of cirrhotic patients in this study. The etiology of cirrhosis was HCV (66.4 %), non-viral causes (23.3 %), and HBV (9.3 %). There was no statistically significant difference between HCC and non-HCC patients as regard viral markers and HCV treatment. According to Barcelona-Clinic Liver Cancer staging, 80 % of patients among HCC group was stage D while 20 % of patients were Stage A -C. Conclusion:HCC is prevalent in cirrhotic patient admitted in Al-Ahrar Teaching Hospital. HCV treatment with DAAs does not raise the risk of HCC occurrence in cirrhotic HCV patients.

Diagnostic Accuracy of Plasma Osteopontin in Egyptian Hepatocellular ‎Carcinoma Patients

“…Despite the fact that using directacting antivirals (DAAs) for the treatment of HCV has improved the possibility of significantly reducing the rate of developing HCC in such patients [7], the consequences of such treatment on the possibility of developing HCC in cirrhotic patients is still questionable [8,9].…”